Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Arliene, Ravelo"'
Autor:
Sikander Ailawadhi, Arliene Ravelo, Carmen D Ng, Bonny Shah, Neil Lamarre, Rongrong Wang, Katherine Eakle, Juliana ML Biondo
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 2 (2024)
Aim: Improved management of chronic lymphocytic leukemia (CLL) has resulted in a growing population of CLL survivors; these patients have a higher risk of developing second primary malignancies (SPMs) versus the general population. This retrospecti
Externí odkaz:
https://doaj.org/article/faadf5cffea44b4aa41ecc512af99f90
Autor:
Stephanie Ossowski, Liisa Lyon, Elizabeth Linehan, Nancy P Gordon, Olga Egorova, Becky Mark, Kimberly Beringer, Thea Abbe, Aida Shirazi, Christine Weldon, Julia Trosman, Arliene Ravelo, Raymond Liu
Publikováno v:
The Permanente Journal. :1-7
Publikováno v:
Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-11 (2017)
Abstract Background Treatment options for advanced nonsquamous non-small cell lung cancer (NSCLC) in the first line include platinum-based doublet therapy with or without bevacizumab. This study examined efficacy outcomes and patient reported outcome
Externí odkaz:
https://doaj.org/article/de2d5752a1e14c30b6d182dc09be2bf1
Autor:
Arliene Ravelo, Kelley Myers, Robyn Brumble, Cooper Bussberg, Brian Koffman, Beenish S. Manzoor, Juliana Biondo, Carol Mansfield
Publikováno v:
Blood. 140:10803-10805
Autor:
Marquita Decker-Palmer, Chia-Wei Lin, Michele Wilson, Cheryl McDade, Komal Bawa, Stacey Kowal, Arliene Ravelo, Elaine Yu, Richard H. Ko
Publikováno v:
Blood. 140:13041-13042
Autor:
Sikander Ailawadhi, Arliene Ravelo, Carmen Ng, Bonny Shah, Rongrong Wang, Katherine Eakle, Juliana Biondo
Publikováno v:
Blood. 140:8040-8041
Autor:
Scott F Huntington, Beenish S Manzoor, Justin T Puckett, Sachin Kamal-Bahl, Hasan Alhasani, Arliene Ravelo, Mahesh Fuldeore, Jalpa A Doshi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S277-S278
Autor:
Scott J. Johnson, Sang Kyu Cho, Suchin Virabhak, Beenish S Manzoor, Sheila Shapouri, Simon Sharmokh, Arliene Ravelo, Kavita Sail, Tatyana Kapustyan, H. Parisé, Matthew S. Davids
Publikováno v:
PharmacoEconomics. 38:941-951
This study aimed to assess the total cost of care (TCC) and budget impact of introducing 12-month fixed duration venetoclax + obinutuzumab (VEN+G) as first-line treatment for chronic lymphocytic leukemia (CLL) from the perspective of a US health plan
Autor:
Esther, Drill, Annie, Qiu, Sheila, Shapouri, Tu My, To, Arliene, Ravelo, Jake, Schade, Keith, Dawson, Matthew, Matasar
Publikováno v:
Oncology (Williston Park, N.Y.). 35(12)
INTRODUCTION: A subcutaneous (SC) formulation of the anti-CD20 monoclonal antibody, rituximab (Rituxan), is approved in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Rituximab-SC (R-SC) has b
Autor:
Arliene Ravelo, Kavita Sail, Beenish S Manzoor, Gijs van de Wetering, Venetia Qendri, Anuja Chatterjee, Sheila Shapouri, Matthew S. Davids
Publikováno v:
Journal of managed carespecialty pharmacy. 27(11)
BACKGROUND: Chronic lymphocytic leukemia (CLL) is a significant health and economic burden in the United States. Treatments include chemoimmunotherapy, such as obinutuzumab (G) plus chlorambucil (Clb) or bendamustine plus rituximab (BR), and chemothe